
Lupin Limited has informed the Exchange regarding a press release dated September 18, 2024, titled "Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda toCommercialize Vonoprazan, a Novel Gastrointestinal Drug in India".
Filed with NSE ·

Lupin Limited has informed the Exchange regarding a press release dated September 18, 2024, titled "Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda toCommercialize Vonoprazan, a Novel Gastrointestinal Drug in India".
6ix hasn’t read this filing yet.
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin